Four lesser-valued cannabis stocks showed positive performance on Monday, defying the broader sector's downtrend. These stocks—Medical Marijuana Inc., TILT Holdings, Trees Corp., and Village Farms International —present potential investment opportunities.
Dyne Therapeutics reported promising Phase 1/2 trial data for DYNE-101 in myotonic dystrophy type 1 and DYNE-251 in Duchenne muscular dystrophy. Improvements in splicing correction, myotonia, muscle strength, and dystrophin expression were observed.
Amgen and AstraZeneca reveal Phase 2a results for Tezspire in severe COPD, showing a 17% reduction in exacerbations, with notable improvements in lung function and quality of life for patients with higher blood eosinophil counts.
Esperion Therapeutics and Otsuka Pharmaceutical report Phase 3 trial results for bempedoic acid in Japan, achieving significant LDL-C reduction in hypercholesterolemia patients. With no serious adverse events, a New Drug Application is planned for late 2024.
Medtronic's SPHERE Per-AF study results reveal the Sphere-9 Catheter's superior safety and efficacy in treating persistent atrial fibrillation compared to the Thermocool SmartTouch SF. The Sphere-9 offers advanced mapping and ablation, showing higher freedom from AFib and fewer complications.
A Delaware jury ordered AstraZeneca to pay Pfizer $107.5 million, ruling that AstraZeneca's lung cancer drug Tagrisso infringed on Pfizer's patents related to cancer treatment.
Discover the implications: BMW Group's 8,000 Mini Cooper imports to the US flagged for banned Chinese components, sparking scrutiny from the Senate. Learn how the Uyghur Forced Labor Prevention Act (UFLPA) is reshaping supply chains and raising concerns about forced labor practices in China's Xinjiang region.